Noninfectious uveitis: A scarcity of randomized clinical trials

Archives of Ophthalmology

Volumn 123, Issue 5, 2005, Pages 682-683

  Okada, Annabelle A ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UVEITIS; INTERMEDIATE UVEITIS; NOTE;

CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS; UVEITIS, INTERMEDIATE; UVEITIS, POSTERIOR;

EID: 18444393046     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.5.682     Document Type: Editorial

References (15)

1. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634-641.
2. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13:2962-2968.
3. Rodriguez F, Krayenbuhl JC, Harrison WB, et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A: an update from the International Kidney Biopsy Registry. Arthritis Rheum. 1996;39:1491-1498.
4. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
5. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc. 1998;30:1240-1242.
6. McCune TR, Thacker LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation. 1998;5:87-92.
7. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol. 2001;2:368-373.
8. Mochizuki M, Kawashima H. Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. Autoimmunity. 1990;8:37-41.
9. de Vries J, Baarsma GS, Zaal MJW, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74:344-349.
10. Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112:138-146.
11. Nussenblatt RB, de Smet MD, Rubin B, et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol. 1993;115:583-591.
12. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc. 1988;20:136-143.
13. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989;1:1093-1096.
14. Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996;103:1054-1063.
15. Jaffe GJ, Ben-Nun J, Quo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033.